Myostatin inhibitors have been intensively studied as pharmaceutical targets for muscle atrophy and mice treated with anti-myostatin antibodies have increased muscle mass and improved muscle insulin sensitivity [54]. This evidence concerns the gene MSTN and muscle atrophy.